ETON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ETON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Eton Pharmaceuticals's gross profit for the three months ended in Dec. 2024 was $6.48 Mil. Eton Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $23.41 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Eton Pharmaceuticals's gross profit for the three months ended in Dec. 2024 was $6.48 Mil. Eton Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $11.65 Mil. Therefore, Eton Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2024 was 55.60%.
Eton Pharmaceuticals had a gross margin of 55.60% for the quarter that ended in Dec. 2024 => Durable competitive advantage
During the past 8 years, the highest Gross Margin % of Eton Pharmaceuticals was 87.05%. The lowest was -1017.95%. And the median was 63.29%.
The historical data trend for Eton Pharmaceuticals's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eton Pharmaceuticals Annual Data | |||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Gross Profit | Get a 7-Day Free Trial | -0.40 | 19.01 | 14.32 | 21.06 | 23.41 |
Eton Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Profit | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
3.63 | 5.01 | 5.63 | 6.30 | 6.48 |
For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Gross Profit distribution charts can be found below:
* The bar in red indicates where Eton Pharmaceuticals's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Eton Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as
Gross Profit (A: Dec. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 39.011 | - | 15.6 | |
= | 23.41 |
Eton Pharmaceuticals's Gross Profit for the quarter that ended in Dec. 2024 is calculated as
Gross Profit (Q: Dec. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 11.647 | - | 5.171 | |
= | 6.48 |
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.41 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Eton Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as
Gross Margin % (Q: Dec. 2024 ) | = | Gross Profit (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 6.48 | / | 11.647 | |
= | 55.60 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Eton Pharmaceuticals (NAS:ETON) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Eton Pharmaceuticals had a gross margin of 55.60% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Thank you for viewing the detailed overview of Eton Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
David Krempa | officer: Chief Business Officer | 29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
Sean Brynjelsen | director, officer: President & CEO | C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010 |
James R. Gruber | officer: Chief Financial Officer | 618 AMES STREET, LIBERTYVILLE IL 60048 |
William Wilson Troutman | officer: CFO, Treasurer & Secretary | 21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
Imprimis Pharmaceuticals, Inc. | 10 percent owner | 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215 |
Jennifer Mckie Adams | director | 5410 TENNESSEE AVE, NASHVILLE TN 37209 |
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
Norbert G Riedel | director | BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015 |
Mark L Baum | director | C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130 |
Paul V Maier | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired • 11-12-2024
By Marketwired • 11-25-2024
By Marketwired • 03-14-2025
By GuruFocus News • 10-28-2024
By Marketwired • 11-06-2024
By GuruFocus Research • 09-13-2024
By GuruFocus News • 03-18-2025
By Marketwired • 02-07-2025
By Marketwired • 12-03-2024
By GuruFocus News • 02-14-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.